Xuerong Biotechnology(SZ:300511)2025-01-27 07:54Financial Performance Expectations - The company expects a net loss for the fiscal year 2024, estimated between 435 million to 650 million CNY, compared to a loss of 188.06 million CNY in the same period last year[4]. - The expected net loss after deducting non-recurring items is projected to be between 455 million to 670 million CNY, compared to a loss of 194.87 million CNY in the previous year[4]. Factors Affecting Performance - The decline in performance is attributed to a weak overall consumer market, intense competition in the edible mushroom industry, and a decrease in product prices[6]. - The company plans to recognize an impairment loss of approximately 280 million to 380 million CNY on relevant assets and asset groups due to market changes and capacity reduction[6]. Non-Recurring Items and Financial Adjustments - Non-recurring gains and losses are expected to impact net profit by approximately 20 million CNY, primarily from government subsidies[6][7]. - The company has communicated with its accounting firm regarding the performance forecast, and there are no significant discrepancies[5]. Financial Reporting - The financial data provided is a preliminary estimate and will be finalized in the 2024 annual report[8].